Multivalent smallpox DNA vaccine delivered by intradermal electroporation drives protective immunity in nonhuman primates against lethal monkeypox challenge

Journal of Infectious Diseases

Volumn 203, Issue 1, 2011, Pages 95-102

  Hirao, Lauren A ^a   Draghia Akli, Ruxandra ^b   Prigge, Jonathan T ^b   Yang, Maria ^b   Satishchandran, Abhishek ^a   Wu, Ling ^a   Hammarlund, Erika ^c   Khan, Amir S ^b   Babas, Tahar ^d   Rhodes, Lowrey ^d   Silvera, Peter ^d   Slifka, Mark ^c   Sardesai, Niranjan Y ^b   Weiner, David B ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b Inovio Pharmaceuticals   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d SOUTHERN RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; SMALLPOX VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN SPECIFICITY; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; DNA MICROARRAY; DRUG DELIVERY SYSTEM; DRUG DESIGN; ELECTROPORATION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; IMMUNE RESPONSE; MACACA; MONKEYPOX VIRUS; NONHUMAN; PRIORITY JOURNAL; SMALLPOX; VIRAL GENE DELIVERY SYSTEM; VIRUS IMMUNITY;

ANIMALS; ANTIBODIES, VIRAL; ELECTROPORATION; HUMANS; MACACA MULATTA; MONKEYPOX; SMALLPOX VACCINE; SURVIVAL ANALYSIS; VACCINES, DNA;

EID: 79851498047     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jiq017     Document Type: Article

References (38)

1. Ladnyj ID, Ziegler P, Kima E. A human infection caused by monkeypox virus in Basankusu Territory, Democratic Republic of the Congo. Bull World Health Organ. 1972; 46:593-7.
2. Parrino J, McCurdy LH, Larkin BD, et al. Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax challenge in vaccinia-naive and vaccinia-immune individuals. Vaccine. 2007; 25:1513-25. (Pubitemid 46074296)
3. von Krempelhuber A, Vollmar J, Pokorny R, et al. A randomized, double-blind, dose-finding Phase II study to evaluate immunogenicity and safety of the third generation smallpox vaccine candidate IMVAMUNE. Vaccine. 2010; 28:1209-16.
4. Hokey DA, Weiner DB. DNA vaccines for HIV: challenges and opportunities. Springer Semin Immunopathol. 2006; 28:267-79. (Pubitemid 44764282)
5. Hooper JW, Thompson E, Wilhelmsen C, et al. Smallpox DNA vaccine protects nonhuman primates against lethal monkeypox. J Virol. 2004; 78:4433-43. (Pubitemid 38501063)
6. Berhanu A, Wilson RL, Kirkwood-Watts DL, et al. Vaccination of BALB/c mice with Escherichia coli-expressed vaccinia virus proteins A27L, B5R, and D8L protects mice from lethal vaccinia virus challenge. J Virol. 2008; 82:3517-29. (Pubitemid 351429927)
7. Earl PL, Americo JL, Wyatt LS, et al. Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox. Nature. 2004; 428:182-5. (Pubitemid 38374314)
8. Heraud JM, Edghill-Smith Y, Ayala V, et al. Subunit recombinant vaccine protects against monkeypox. J Immunol. 2006; 177: 2552-64. (Pubitemid 44201014)
9. Hooper JW, Custer DM, Thompson E. Four-gene-combination DNA vaccine protects mice against a lethal vaccinia virus challenge and elicits appropriate antibody responses in nonhuman primates. Virology. 2003; 306:181-95. (Pubitemid 36293408)
10. Vanderplasschen A, Hollinshead M, Smith GL. Intracellular and extracellular vaccinia virions enter cells by different mechanisms. J Gen Virol. 1998; 79(pt 4);877-87.
11. Putz MM, Midgley CM, Law M, Smith GL. Quantification of antibody responses against multiple antigens of the two infectious forms of Vaccinia virus provides a benchmark for smallpox vaccination. Nat Med. 2006; 12:1310-5. (Pubitemid 44706934)
12. Rodriguez JF, Janeczko R, Esteban M. Isolation and characterization of neutralizing monoclonal antibodies to vaccinia virus. J Virol. 1985; 56:482-8. (Pubitemid 16192335)
13. Brown E, Senkevich TG, Moss B. Vaccinia virus F9 virion membrane protein is required for entry but not virus assembly, in contrast to the related L1 protein. J Virol. 2006; 80:9455-64. (Pubitemid 44435624)
14. Lin CL, Chung CS, Heine HG, Chang W. Vaccinia virus envelope H3L protein binds to cell surface heparan sulfate and is important for intracellular mature virion morphogenesis and virus infection in vitro and in vivo. J Virol. 2000; 74:3353-65. (Pubitemid 30143761)
15. Davies DH, McCausland MM, Valdez C, et al. Vaccinia virus H3L envelope protein is a major target of neutralizing antibodies in humans and elicits protection against lethal challenge in mice. J Virol. 2005; 79:11724-33. (Pubitemid 41279291)
16. Wolffe EJ, Vijaya S, Moss B. A myristylated membrane protein encoded by the vaccinia virus L1R open reading frame is the target of potent neutralizing monoclonal antibodies. Virology. 1995; 211:53-63.
17. Seki M, Oie M, Ichihashi Y, Shida H. Hemadsorption and fusion inhibition activities of hemagglutinin analyzed by vaccinia virus mutants. Virology. 1990; 175:372-84. (Pubitemid 20133439)
18. Hooper JW, Custer DM, Schmaljohn CS, Schmaljohn AL. DNA vaccination with vaccinia virus L1R and A33R genes protects mice against a lethal poxvirus challenge. Virology. 2000; 266:329-39. (Pubitemid 30070637)
19. Galmiche MC, Goenaga J, Wittek R, Rindisbacher L. Neutralizing and protective antibodies directed against vaccinia virus envelope antigens. Virology. 1999; 254:71-80. (Pubitemid 29391715)
20. Edghill-Smith Y, Golding H, Manischewitz J, et al. Smallpox vaccine-induced antibodies are necessary and sufficient for protection against monkeypox virus. Nat Med. 2005; 11:740-7. (Pubitemid 41021206)
21. Panchanathan V, Chaudhri G, Karupiah G. Protective immunity against secondary poxvirus infection is dependent on antibody but not on CD4 or CD8 T-cell function. J Virol. 2006; 80:6333-8. (Pubitemid 43927436)
22. Cristillo AD, Weiss D, Hudacik L, et al. Persistent antibody and T cell responses induced by HIV-1 DNA vaccine delivered by electroporation. Biochem Biophys Res Commun. 2008; 366:29-35. (Pubitemid 350297215)
23. Feltquate DM, Heaney S, Webster RG, Robinson HL. Different T helper cell types and antibody isotypes generated by saline and gene gun DNA immunization. J Immunol. 1997; 158:2278-84. (Pubitemid 127470012)
24. Hebel H, Attra H, Khan A, Draghia-Akli R. Successful parallel development and integration of a plasmid-based biologic, container/closure system and electrokinetic delivery device. Vaccine. 2006; 24:4607-14. (Pubitemid 44218839)
25. Hirao LA, Wu L, Khan AS, et al. Combined effects of IL-12 and electroporation enhances the potency of DNA vaccination in macaques. Vaccine. 2008; 26:3112-20.
26. Boyer JD, Robinson TM, Kutzler MA, et al. SIV DNA vaccine coadministered with IL-12 expression plasmid enhances CD8 SIV cellular immune responses in cynomolgus macaques. J Med Primatol. 2005; 34:262-70. (Pubitemid 41179588)
27. Hooper JW, Ferro AM, Golden JW, et al. Molecular smallpox vaccine delivered by alphavirus replicons elicits protective immunity in mice and non-human primates. Vaccine. 2009; 28:494-511.
28. Nigam P, Earl PL, Americo JL, et al. DNA/MVA HIV-1/AIDS vaccine elicits long-lived vaccinia virus-specific immunity and confers protection against a lethal monkeypox challenge. Virology. 2007; 366:73-83. (Pubitemid 47314398)
29. Jordan R, Goff A, Frimm A, et al. ST-246(R) antiviral efficacy in a nonhuman primate monkeypox model: determination of the minimal effective dose and human dose justification. Antimicrob Agents Chemother. 2009; 53(5):1817-22.
30. Andrew WA. New generation smallpox vaccines: a review of preclinical and clinical data. Rev Med Virol. 2008; 18:217-31.
31. Hooper JW, Golden JW, Ferro AM, King AD. Smallpox DNA vaccine delivered by novel skin electroporation device protects mice against intranasal poxvirus challenge. Vaccine. 2007; 25:1814-23. (Pubitemid 46176327)
32. Otero M, Calarota SA, Dai A, De Groot AS, Boyer JD, Weiner DB. Efficacy of novel plasmid DNA encoding vaccinia antigens in improving current smallpox vaccination strategy. Vaccine. 2006; 24:4461-70. (Pubitemid 44218846)
33. Demkowicz WE,Maa JS, Esteban M. Identification and characterization of vaccinia virus genes encoding proteins that are highly antigenic in animals and are immunodominant in vaccinated humans. J Virol. 1992; 66:386-98.
34. Sivapalasingam S, Kennedy JS, Borkowsky W, et al. Immunological memory after exposure to variola virus, monkeypox virus, and vaccinia virus. J Infect Dis. 2007; 195:1151-9. (Pubitemid 46543446)
35. Fogg CN, Americo JL, Lustig S, et al. Adjuvant-enhanced antibody responses to recombinant proteins correlates with protection of mice and monkeys to orthopoxvirus challenges. Vaccine. 2007; 25:2787-99. (Pubitemid 46412575)
36. Golden JW, Josleyn MD, Hooper JW. Targeting the vaccinia virus L1 protein to the cell surface enhances production of neutralizing antibodies. Vaccine. 2008; 26:3507-15.
37. Shinoda K, Wyatt LS, Irvine KR, Moss B. Engineering the vaccinia virus L1 protein for increased neutralizing antibody response after DNA immunization. Virol J. 2009; 6:28.
38. Crotty S, Felgner P, Davies H, Glidewell J, Villarreal L, Ahmed R. Cutting edge: long-term B cell memory in humans after smallpox vaccination. J Immunol. 2003; 171:4969-73. (Pubitemid 37432774)